

GUILFORD PHARMACEUTICALS INC  
Form SC 13D/A  
May 05, 2004

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D**

**Under The Securities Exchange Act of 1934**

**(Amendment No. 1)\***

GUILFORD PHARMACEUTICALS, INC.

---

(Name of Issuer)

COMMON STOCK, \$.01 PAR VALUE

---

(Title of Class of Securities)

401829106

---

(CUSIP Number)

Edgar Filing: GUILFORD PHARMACEUTICALS INC - Form SC 13D/A

David J. Scott, Esq.

Senior Vice President,

General Counsel and Secretary

One Amgen Center Drive

Thousand Oaks, CA 91320-1799

(805) 447-1000

---

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 1, 2002

---

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. "

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

1. Name of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)

Amgen Inc.

---

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ..

(b) ..

---

3. SEC Use Only

---

4. Source of Funds (See Instructions)

WC

---

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ..

---

6. Citizenship or Place of Organization

Delaware

---

NUMBER OF 7. Sole Voting Power

SHARES

BENEFICIALLY None

---

OWNED BY 8. Shared Voting Power

EACH

REPORTING None

---

PERSON 9. Sole Dispositive Power

WITH

None

---

10. Shared Dispositive Power

None

---

11. Aggregate Amount Beneficially Owned by Each Reporting Person

None

---

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

---

13. Percent of Class Represented by Amount in Row (11)

None

---

14. Type of Reporting Person (See Instructions)

CO

---

The statement on Schedule 13D filed by Amgen Inc. ( Amgen ) on January 28, 1997 (the Initial Statement ) relating to the Common Stock, \$0.01 par value per share (the Common Stock ) of Guilford Pharmaceuticals, Inc., a Delaware corporation (the Issuer ) is hereby amended by this Amendment 1 to Schedule 13D. The Reporting Person no longer has beneficial ownership of any of the Issuer s Common Stock for reporting under Section 13(d) of the Securities Exchange Act of 1934, as amended. Unless otherwise indicated, all capitalized terms used herein but not defined herein shall have the meaning assigned to them in the Schedule 13D.

**Item 5 Interest in Securities of the Issuer**

Item 5 of the Initial Statement is hereby amended and supplemented with the following:

- (a) On October 1, 2002, the Warrant issued to the Reporting Person to purchase up to 700,000 shares of Issuer s Common Stock expired without the Reporting Person exercising its right to purchase any of Issuer s shares. The expiration of the Warrant resulted in the Reporting Person falling below the five percent threshold of ownership of Issuer s Common Stock.
- (b) In 2003, the remaining 640,095 shares of Issuer s Common Stock were sold. As of the date of this Amendment No. 1 to Schedule 13D, the Reporting Person does not beneficially own any shares of the Issuer s Common Stock.

CUSIP No. 401829106

13D

Page 4 of 4 Pages

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: May 5, 2004

AMGEN INC.

By: /s/ David J. Scott

---

Name: David J. Scott  
Title: Senior Vice President, General Counsel and  
Secretary